Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia (AML)
Pharma
Daiichi Sankyo, Astellas, Takeda—Fierce Pharma Asia
Daiichi snagged a long-delayed FLT3 nod. Astellas signed another protein degrader deal. Takeda's neuroscience outfit ran into a setback. And more.
Angus Liu
Jul 28, 2023 7:56am
Daiichi scores FDA nod for leukemia med Vanflyta
Jul 21, 2023 10:05am
In expansion bid, Astellas' Xospata comes up short again
Mar 9, 2023 10:11am
Rigel's nod for Rezlidhia sets up battle with Servier in AML
Dec 2, 2022 9:57am
Particulates have prompted yet another injectable drug recall
Mar 30, 2022 9:45am
